General
Preferred name
MW-150
Synonyms
MW-150 dihydrochloride dihydrate ()
MW01-18-150SRM dihydrochloride dihydrate ()
MW01-18-150SRM ()
MW150 ()
MW 150 ()
P&D ID
PD120148
CAS
1628502-91-9
Tags
available
drug candidate
Drug Status
investigational
Max Phase
2.0
Drug indication
Alzheimer disease
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION MW150 is a novel, pharmacologically selective p38α MAP kinase (MAPK14) inhibitor . It is CNS-penetrant and is being pursued as a clinical lead for neurological disorders. MW150 is claimed in patent WO2014145485A2 that was filed by The Trustees Of Columbia University In The City Of New York . (GtoPdb)
DESCRIPTION MW150 (MW01-18-150SRM) is a selective, CNS penetrant, and orally active inhibitor of p38¦Á MAPK with a Ki of 101 nM. MW-150 inhibits the ability of the endogenous p38¦Á MAPK to phosphorylate an endogenous substrate MK2 in activated glia[1].
PRICE 127
DESCRIPTION MW-150 (MW01-18-150SRM) is a unique, selective, CNS-penetrant, and orally active inhibitor of p38?? MAPK with a Ki of 101 nM.
DESCRIPTION MW-150 (MW01-18-150SRM) is a unique, selective, CNS-penetrant, and orally active inhibitor of p38α MAPK with a Ki of 101 nM. (TargetMol Bioactive Compound Library)
Compound Sets
6
Cayman Chemical Bioactives
ChEMBL Drugs
Guide to Pharmacology
MedChem Express Bioactive Compound Library
Other bioactive compounds
TargetMol Bioactive Compound Library
External IDs
20
Properties
(calculated by RDKit )
Molecular Weight
381.2
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
0
Rotatable Bonds
3
Ring Count
5
Aromatic Ring Count
4
cLogP
4.11
TPSA
45.15
Fraction CSP3
0.21
Chiral centers
0.0
Largest ring
6.0
QED
0.53
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
Autophagy
p38 MAPK
p38α
Pathway
MAPK/ERK Pathway
MAPK
Source data